ATE280152T1 - Acetylenische sulfonamid-thiol-tace-inhibitoren - Google Patents

Acetylenische sulfonamid-thiol-tace-inhibitoren

Info

Publication number
ATE280152T1
ATE280152T1 AT00905787T AT00905787T ATE280152T1 AT E280152 T1 ATE280152 T1 AT E280152T1 AT 00905787 T AT00905787 T AT 00905787T AT 00905787 T AT00905787 T AT 00905787T AT E280152 T1 ATE280152 T1 AT E280152T1
Authority
AT
Austria
Prior art keywords
acetyleneic
sulfonamide
thiol
tace inhibitors
disease
Prior art date
Application number
AT00905787T
Other languages
English (en)
Inventor
Jeremy Ian Levin
James Ming Chen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE280152T1 publication Critical patent/ATE280152T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
AT00905787T 1999-01-27 2000-01-27 Acetylenische sulfonamid-thiol-tace-inhibitoren ATE280152T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23839399A 1999-01-27 1999-01-27
PCT/US2000/002143 WO2000044716A1 (en) 1999-01-27 2000-01-27 Acetylenic sulfonamide thiol tace inhibitors

Publications (1)

Publication Number Publication Date
ATE280152T1 true ATE280152T1 (de) 2004-11-15

Family

ID=22897697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905787T ATE280152T1 (de) 1999-01-27 2000-01-27 Acetylenische sulfonamid-thiol-tace-inhibitoren

Country Status (21)

Country Link
EP (1) EP1149074B1 (de)
JP (1) JP2002535386A (de)
KR (1) KR20010101691A (de)
CN (1) CN1224612C (de)
AT (1) ATE280152T1 (de)
AU (1) AU766192B2 (de)
BR (1) BR0007727A (de)
CA (1) CA2356480A1 (de)
CZ (1) CZ20012545A3 (de)
DE (1) DE60015079T2 (de)
DK (1) DK1149074T3 (de)
EA (1) EA200100811A1 (de)
ES (1) ES2230064T3 (de)
HK (1) HK1038915A1 (de)
HU (1) HUP0105282A3 (de)
IL (1) IL144347A0 (de)
NO (1) NO20013638D0 (de)
NZ (1) NZ512306A (de)
PL (1) PL350420A1 (de)
WO (1) WO2000044716A1 (de)
ZA (1) ZA200105069B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
WO2003033477A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
DK1465861T3 (da) 2001-12-20 2009-08-31 Bristol Myers Squibb Co Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
EP3860608A1 (de) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr-inhibitoren zur behandlung von keratosen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE233552T1 (de) * 1996-07-22 2003-03-15 Monsanto Co Thiol-sulfonen als metalloproteinaseinhibitoren
BR9710752A (pt) * 1996-07-22 1999-08-17 Monsanto Co Inbidores de metaloprotease de sulfonamida de tiol

Also Published As

Publication number Publication date
JP2002535386A (ja) 2002-10-22
CN1224612C (zh) 2005-10-26
DE60015079D1 (de) 2004-11-25
EA200100811A1 (ru) 2002-12-26
ES2230064T3 (es) 2005-05-01
HUP0105282A3 (en) 2005-04-28
EP1149074A1 (de) 2001-10-31
NO20013638L (no) 2001-07-24
WO2000044716A1 (en) 2000-08-03
AU766192B2 (en) 2003-10-09
AU2741700A (en) 2000-08-18
HUP0105282A2 (hu) 2002-05-29
DK1149074T3 (da) 2005-01-10
ZA200105069B (en) 2002-09-20
CN1337947A (zh) 2002-02-27
NZ512306A (en) 2003-10-31
CZ20012545A3 (cs) 2002-04-17
CA2356480A1 (en) 2000-08-03
NO20013638D0 (no) 2001-07-24
KR20010101691A (ko) 2001-11-14
EP1149074B1 (de) 2004-10-20
HK1038915A1 (zh) 2002-04-04
BR0007727A (pt) 2001-10-30
IL144347A0 (en) 2002-05-23
DE60015079T2 (de) 2005-03-03
PL350420A1 (en) 2002-12-16

Similar Documents

Publication Publication Date Title
WO2000044709A3 (en) ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
BG105736A (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
DE60015079D1 (de) Acetylenische sulfonamid-thiol-tace-inhibitoren
NZ512446A (en) Alkynyl containing hydroxamic acid compounds as TACE inhibitors
DE60135029D1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
SI1480961T1 (sl) Inhibitorji dpiv na osnovi glutaminila
WO2003093269A3 (de) Substituierte pyrazolo-pyrimidin-4-one
ATE235472T1 (de) N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepi - 3-yl)-3-amide
EA200001152A1 (ru) СУКЦИНАМИДНЫЕ ИНГИБИТОРЫ ИНТЕРЛЕЙКИН - 1b - КОНВЕРТИРУЮЩЕГО ФЕРМЕНТА
PL357510A1 (en) Removal of chloride from phosphonomethyliminodiacetic acid process
DE60012302D1 (en) Acetylenische arylsulfonamid- und phosphinsäureamid-hydroxamsäure-derivate als tace inhibitoren
DK1109818T3 (da) Phosphoepoxider, fremgangsmåder til deres fremstilling og deres anvendelser
SI1377574T1 (de)
DK1620423T3 (da) Fremgangsmåde til fremstillingen af (4-hydroxy-6-oxotetrahydropyran-2-yl) acetonitril og derivater deraf
EA200100808A1 (ru) ГИДРОКСАМОВЫЕ КИСЛОТЫ НА ОСНОВЕ АЦЕТИЛЕНОВОГО b-СУЛЬФОНАМИДО И АМИДА ФОСФИНОВОЙ КИСЛОТЫ, КАК ИНГИБИТОРЫ TACE
MXPA04004010A (es) Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz.
EA200100814A1 (ru) Применение ацетиленового орто-сульфонамида и фосфинамидозамещенных бициклических гетероарильных гидроксамовых кислот в качестве ингибиторов tace
EA200100805A1 (ru) Ингибиторы tace на основе гетероарилацетиленсульфонамида и фосфинамида гидроксамовой кислоты
BR0311590A (pt) Agonistas de brs-3 não-peptìdicos
NO20014845L (no) Anvendelse av arylalkanoylpyridaziner
WO2002010160A3 (de) Substituierte heterocyclylalkylamino-1,3,5-triazine
ATE303390T1 (de) Sulfat von cephemverbindung
EP1385510A4 (de) Prodigiosin-zusammensetzung zur behandlung von rheumatoider arthritis
DK0691986T3 (da) Hidtil ukendte fremgangsmåder og mellemproduktforbindelser til fremstillingen af blodpladeglycoprotein IIb/IIIa-inhibitorer
ITMI20001004A0 (it) Procedimento per la produzione di blocchi di schiume pluricomponenti,nonche' impianti per la sua attuazione.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties